Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Newsoara Acquires Asia Rights to NASH Candidate in $26 Million Deal

publication date: Mar 11, 2019

Newsoara Biopharma of Shanghai signed a $26 million agreement with TaiwanJ Pharma that gives Newsoara rights to develop a treatment for nonalcoholic steatohepatitis (NASH) in Asia (except for Taiwan). The candidate, JKB-122, is a long-acting small molecule TLR4 antagonist that has shown anti-fibrotic, immuno-modulating and anti-inflammatory activity in various chronic liver diseases. JKB-122 is currently in a Phase II trial. TaiwanJ will receive a $2 million upfront payment and up to $24 million in milestones. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020